0The Question Not Asked: The Challenge of Pleiotropic Genetic Tests
- 1 June 1998
- journal article
- research article
- Published by Project MUSE in Kennedy Institute of Ethics Journal
- Vol. 8 (2) , 131-144
- https://doi.org/10.1353/ken.1998.0013
Abstract
Nearly all of the literature on the ethical, legal, or social issues surrounding genetic tests has proceeded on the assumption that any particular test for a gene mutation yields information about only one disease condition. Even though the phenomenon of pleiotropy, where a single gene has multiple, apparently unrelated phenotypic effects, is widely recognized in genetics, it has not had much significance for genetic testing until recently. In this article, I examine a moral dilemma created by one sort of pleiotropic testing, APOE genotyping, which can yield information about the risk of two different conditions--coronary heart disease and Alzheimer's disease. A physician administering APOE testing for the beneficial purpose of assessing the risk of heart disease may discover medically useless and socially harmful information about the patient's risk of Alzheimer's disease. I explore how much providers should disclose to patients about pleiotropic test results and whether patients are obligated to know as much about their genetic condition as possible.Keywords
This publication has 5 references indexed in Scilit:
- Disowning Knowledge: Issues in Genetic TestingPublished by Taylor & Francis ,2017
- The Rule of Double Effect — A Critique of Its Role in End-of-Life Decision MakingNew England Journal of Medicine, 1997
- The Clinical Introduction of Genetic Testing for Alzheimer DiseaseAn Ethical PerspectiveJAMA, 1997
- Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart DiseaseJAMA, 1994
- Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.Proceedings of the National Academy of Sciences, 1993